Spero Therapeutics, Inc. Common Stock
Symbol: SPRO (NASDAQ)
Company Description:
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
- Today's Open: $1.89
- Today's High: $1.969
- Today's Low: $1.862
- Today's Volume: 221.93K
- Yesterday Close: $1.88
- Yesterday High: $1.91
- Yesterday Low: $1.84
- Yesterday Volume: 385.87K
- Last Min Volume: 300
- Last Min High: $1.969
- Last Min Low: $1.966
- Last Min VWAP: $1.967
- Name: Spero Therapeutics, Inc. Common Stock
- Website: https://www.sperotherapeutics.com
- Listed Date: 2017-11-02
- Location: CAMBRIDGE, MA
- Market Status: Active
- CIK Number: 0001701108
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $105.80M
- Round Lot: 100
- Outstanding Shares: 56.28M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-03 | 4 | View |
2025-09-03 | 4 | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-12 | S-8 | View |
2025-08-12 | 10-Q | View |
2025-08-12 | 8-K | View |
2025-06-18 | 8-K | View |
2025-06-16 | 4 | View |
2025-06-16 | 4 | View |
2025-06-16 | 4 | View |
2025-06-16 | 4 | View |
2025-06-16 | 4 | View |
2025-06-16 | 4 | View |
2025-06-16 | 4 | View |
2025-06-16 | 4 | View |
2025-05-28 | 8-K | View |
2025-05-13 | 8-K | View |
2025-05-13 | 10-Q | View |
2025-05-06 | 4 | View |
2025-04-28 | ARS | View |